Loading live market data…

Mereo BioPharma Group plc

NASDAQ:MREO

$0.314 USD

-$0.01 (-2.18%)

Volume
546.77K
Average Volume
3.47M
Market Capitalization
$50.12M
P/E Ratio
-1.40
Dividend Yield
0.00%
Price Target
$2.50
Year High
$2.37
Year Low
$0.20
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$6.48

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Denise Vera Scots-Knight
Industry Biotechnology
Sector Healthcare
Current Symbol MREO
CUSIP 589492107
CIK 0001719714
Web https://www.mereobiopharma.com
Phone 44 33 3023 7300
Currency USD
Employees 39
Country GB

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 6.48
Quick Ratio 6.48
Cash Ratio 5.86

Sales & Book Value

Annual Sales $500K
Price / Sales 100.24
Cash Flow -0.17
Price / Cash Flow -1.86
Price / Book 1.48

Price Target and Rating

Average Stock Price Forecast $2.50
High Stock Price Forecast $8.00
Low Stock Price Forecast $0.50
Forecast Upside/Downside -87.44%
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 8 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.26
Trailing P/E Ratio -1.40
PEG Ratio -0.01
P/E Growth -0.01
Net Income $-41.88M
Net Margin -7139.75%
Pretax Margin -7158.72%
Return on Equity -81.25%
Return on Assets -87.90%

Financials Score

AltmanZ Score -15.09
Piotroski Score 2.00
Working Capital 33.86M
Total Assets 40.61M
Ebit -40.54M
Market Cap 51.24M
Total Liabilities 6.56M

Poll Results

About Mereo BioPharma Group plc (NASDAQ:MREO) Stock

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addr ... essing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.

4basebio Announces Appointment of Chief Financial Officer and Board Changes

2026-05-14 07:00:00

Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period.

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

2026-05-12 07:30:00

LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments.

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

2026-05-12 07:30:00

LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments.

Frequently Asked Questions

What is the current Mereo BioPharma Group plc (MREO) stock price?

Mereo BioPharma Group plc(NASDAQ:MREO) stock price is $0.314 in the last trading session. During the trading session, MREO stock reached the peak price of $2.37 while $0.2 was the lowest point it dropped to. The percentage change in MREO stock occurred in the recent session was --2.18% while the dollar amount for the price change in MREO stock was -$-0.01.

MREO's industry and sector of operation?

The NASDAQ listed MREO is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of MREO?

Denise Scots-Knight | Co-Founder, Chief Executive Officer & Executive Director
Charles Sermon | Co-Founder, General Counsel, Business Development & Company Secretary
Jackie Parkin | Senior Vice President & Therapeutic Head
John A. Lewicki | Chief Scientific Officer
Ogun Sazova | VP & Head of Medical Affairs

How many employees does MREO have?

Number of MREO employees currently stands at 39. MREO operates from One Cavendish Place, London, GL W1G 0QF, GB.

Link for MREO official website?

Official Website of MREO is: https://www.mereobiopharma.com

How do I contact MREO?

MREO could be contacted at phone #44 33 3023 7300 and can also be accessed through its website. MREO operates from One Cavendish Place, London, GL W1G 0QF, GB.

How many shares of MREO are traded daily?

The average number of MREO shares traded daily for last 3 months was 3.47M.

What is the market cap of MREO currently?

The market value of MREO currently stands at $50.12M with its latest stock price at $0.314